Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection

Table 3 Efficacy of direct-acting antivirals based, (peg-)-interferon-free antiviral therapy in patients with hepatitis C virus liver graft infection in controlled, prospective trials

Ref.	Therapy regime	Treatment duration (wk)	Genotype1	n	SVR12
Charlton et al[19] (SOLAR-1)1	LDV/RBV + RBV	12-24	1, 4	2292	214/229 (93%)
1Charlton et al[82]	SOF + RBV	24	1, 3, 4	40	28/40 (70%)
Kwo et al[84] (CORAL-1)	DSV/OMV/PTV/r + RBV	24	1	34	33/34 (97%)
Manns et al[31,72] (SOLAR-2)	LDV/SOF +RBV	12 or 24	1, 4	1683	146/151 (97%)
Poordad et al[36] (ALLY-1)1	DCV/SOF + RBV	12	1, 2, 3, 4, 64	532	50/53 (94%)
Reddy et al[83]	SOF/LDV + RBV	12-24	1, 4	223	120/129 (93%)5

¹Mainly patients with genotype 1;

²The complete study included patients prior and after liver transplantation;

³Preliminary results with regard to publication status or completed SVR12 (SVR not available in all patients enrolled into the study);

⁴Only one patient had GT 2, 4 or 6;

⁵Interims SVR4 results. LDV: Ledipasvir; RBV: Ribavirin; SMV: Simeprevir; SOF: Sofosbuvir; OMV: Ombitasvir; PTV/r: Paritaprevir/ritonavir; SVR12: Sustained virologic response 12 wk after end of treatment.